Literature DB >> 16540192

Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study.

Simon G Thompson1, Richard M Nixon, Richard Grieve.   

Abstract

Differences in the mean, spread and skewness of cost data collected from different countries present problems for analysis and interpretation. Here we develop generalised linear multilevel models to estimate the effects of patient and national characteristics on costs. Using gamma distributions and multiplicative effects for patient characteristics fitted the data better than models which assumed normal distributions or estimated additive effects. A multilevel gamma model is employed to allow for heterogeneity in the effects of patient case-mix across centres. Analysis of multinational cost data must recognise differences in mean, spread and skewness across centres, as well as the data's hierarchical structure.

Entities:  

Mesh:

Year:  2006        PMID: 16540192     DOI: 10.1016/j.jhealeco.2006.02.001

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  15 in total

1.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease.

Authors:  Paddy Gillespie; Eamon O'Shea; Andrew W Murphy; Susan M Smith; Mary C Byrne; Molly Byrne; Margaret E Cupples
Journal:  Eur J Health Econ       Date:  2011-05-03

Review 4.  Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis.

Authors:  Hege Urdahl; Andrea Manca; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Bayesian modelling of healthcare resource use in multinational randomized clinical trials.

Authors:  Aline Gauthier; Andrea Manca; Susan Anton
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.

Authors:  Andrea Manca; Paul C Lambert; Mark Sculpher; Nigel Rice
Journal:  Med Decis Making       Date:  2007-07-19       Impact factor: 2.583

Review 7.  Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies.

Authors:  Raymond Oppong; Sue Jowett; Tracy E Roberts
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials.

Authors:  Manuel Gomes; Edmond S-W Ng; Richard Grieve; Richard Nixon; James Carpenter; Simon G Thompson
Journal:  Med Decis Making       Date:  2011-10-19       Impact factor: 2.583

9.  Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial.

Authors:  Paddy Gillespie; Eamon O'Shea; Mary Clare O'Hara; Sean F Dinneen
Journal:  Trials       Date:  2014-06-14       Impact factor: 2.279

10.  The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial.

Authors:  Paddy Gillespie; Eamon O'Shea; Dympna Casey; Kathy Murphy; Declan Devane; Adeline Cooney; Lorraine Mee; Collette Kirwan; Bernard McCarthy; John Newell
Journal:  BMJ Open       Date:  2013-11-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.